The overlap between the ebola and covid networks run by Gates and Fauci as dual use bioweapons, biodefense research

 The scientists and institutions, grans involved in the  Ebola gain-of-function overlap with the people, research networks and arguments that became central to the covid-origin controversy and at the centre of those two networks are Gates and Fauci.

The strongest version of the overlap

1. Gates funded parts of the Ebola network.

Gates funding went to Corgenix for the ReEBOV Ebola diagnostic and to the Broad Institute for Ebola genomic sequencing. The Foundation's grant database is the primary place to establish the recipients and stated purposes.

So:

Gates → Corgenix/Broad → Ebola research

2. Those projects intersected with the Garry/KGH/VHFC network

The Ebola work at Kenema wasn't an isolated diagnostic project. KGH had an established viral-hemorrhagic-fever research program, and Garry's group worked with KGH and the wider VHFC. Garry subsequently described having worked with KGH for nearly two decades.

So you have:

Gates-funded Ebola projects ↔ Garry/VHFC ↔ KGH. The same KGH research infrastructure and cohorts subsequently entered coronavirus research

This is probably the most interesting direct overlap.

The pre-COVID Sierra Leone study explicitly says that researchers used blood samples collected before the COVID pandemic from Lassa fever and Ebola survivors and their contacts. It was conducted through the KGH/VHFC research setting.

And the author list includes Robert Garry and Kristian Andersen. Andersen's publication record identifies the study as a 2021 paper on cross-reactive SARS-CoV-2/MERS-CoV antibodies in pre-COVID Sierra Leone blood samples.

There is an actual biological/research continuity:

Ebola/Lassa survivor cohorts → stored pre-pandemic specimens → SARS-CoV-2 serological research.

Garry and Andersen then move directly into the COVID-origin debate

Garry's congressional testimony provides a particularly clear bridge. He says that after the first SARS-CoV-2 sequence was released, he participated with other scientists in the molecular/phylogenetic analysis that became The Proximal Origin of SARS-CoV-2. He explicitly places that work in the context of his nearly 20 years of work with KGH.

The chain is approximately:

Gates-funded Ebola research

↓

KGH / VHFC

↓

Garry + Andersen + associated institutions

↓

Ebola/Lassa survivor cohorts and biological samples

↓

pre-COVID SARS-CoV-2 research in Sierra Leone

↓

Garry + Andersen

↓

Proximal Origin

A. Funding overlap — established

Gates funded significant Ebola research involving institutions and researchers in this network.

B. Scientific/personnel/sample overlap — established

KGH/VHFC's Ebola/Lassa infrastructure, cohorts and researchers subsequently participated in coronavirus research.

C Gates funded significant covid research through EcoHealth.

The same institutional and scientific ecosystem that received Gates support during the Ebola outbreak subsequently used Ebola/Lassa survivor material and the established KGH/VHFC research infrastructure for pre-pandemic coronavirus research, while key researchers from that ecosystem—particularly Garry and Andersen—went on to participate in the SARS-CoV-2 origin analysis that produced Proximal Origin.

The Covid track

Coronavirus research—particularly research on SARS, MERS, and bat coronaviruses—was already active in 2014.

What was happening in 2014?

Fauci s pardon extends back to 2014.

The original NIH award was to EcoHealth Alliance, which subcontracted part of the work to WIV. GAO later identified a WIV NIH subaward of about $598,000 over the relevant five-year period.

There was also USAID's PREDICT program, which had supported coronavirus surveillance involving WIV/EcoHealth before and during this period.

What was actually being experimented on?

This is where the story becomes important.

The researchers were looking for SARS-like coronaviruses in bats, particularly viruses related to the virus that caused the 2003 SARS outbreak.

A major earlier discovery was published in 2013 by Shi Zhengli, Xing-Yi Ge, Peter Daszak and colleagues: they identified a bat coronavirus called WIV1 that could use the human SARS coronavirus receptor ACE2.

That work established that some naturally occurring bat coronaviruses possessed characteristics that potentially allowed them to infect human cells.

The 2014 program expanded this kind of investigation.

2015 — the particularly controversial experiment

This is probably the experiment you've heard about.

In 2015, a team involving:

Ralph Baric — University of North Carolina

Vineet Menachery and other UNC researchers

Zhengli Shi

Xing-Yi Ge — WIV

So it is accurate to say that U.S. federal money supported research involving WIV, but it is misleading to describe it as NIH directly giving a multi-million-dollar grant to the Wuhan laboratory.

published a paper in Nature Medicine called:

“A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence.”

They took the spike protein from a bat coronavirus called SHC014 and put it onto a mouse-adapted SARS coronavirus backbone.

That created a chimeric virus.

They then tested it for characteristics including:

ability to use human ACE2;

replication in human airway cells;

replication in mice; and

susceptibility to existing SARS antibodies/vaccine approaches.

They also generated an infectious version of SHC014 itself using reverse genetics.

This was a genuine gain-of-function-type experiment, although terminology matters: scientists and policymakers have disagreed about exactly how this work should be classified under different definitions of “gain of function.”

The paper itself says the experiments involving the full-length and chimeric SHC014 viruses were initiated before the U.S. October 2014 funding pause and were subsequently reviewed and approved for continuation.

.

Funding

The 2015 paper acknowledges:

NIH/NIAID

NIH/National Institute on Aging

USAID PREDICT through EcoHealth Alliance

Chinese National Natural Science Foundation

among its sources of support.

Why October 2014 matters

Claim Evidence

Coronavirus research existed at WIV before COVID Yes

WIV/EcoHealth studied bat SARS-related coronaviruses Yes

U.S. government money supported some of this research Yes

NIH money reached WIV indirectly through EcoHealth Yes

Researchers performed experiments altering SARS-related coronavirus genomes Yes

A 2015 experiment created a SARS-like chimeric virus Yes

Some experiments tested infection of human airway cells and mice Yes

There is an overlap between the Kenema, Ebola and the Wuhan coronavirus network

Kenema/VHFC

NIH/NIAID → Tulane/VHFC → KGH

Gates → various research/response projects

DTRA → USAMRIID/Metabiota-related work

CDC → outbreak diagnostics

Broad/Harvard/Scripps/UTMB → scientific collaboration

Wuhan/EcoHealth

NIH/NIAID → EcoHealth Alliance → WIV

USAID/PREDICT → EcoHealth and collaborators

Chinese government funding → Chinese research institutions

WIV ↔ UNC/Baric and other international collaborators

Robert Garry and Kristian Anderson and Ian Lipkin were 3 of the five authors The Proximal Origin of SARS-CoV-2  who were also involved in the Kenema ebola genomic research.

The Gates Foundation funds research in several areas that are legitimately considered dual-use from a biosecurity perspective, particularly pathogen genomics, sequencing, diagnostics, epidemiology, and One Health surveillance.

Examples from its current public grant database:

• Pathogen genomic sequencing: In March 2026, the Foundation committed $25,000 for an economic study concerning procurement and delivery of pathogen genomic sequencing across African public-health programs.
• Genomic analysis: In June 2026, it committed $749,667 to the Broad Institute to develop pathogen-genomic data-analysis pipelines for malaria and other pathogens of public-health importance in Africa.
• One Health / animal-human-environment surveillance: In 2026, it committed $508,992 to Temasek Life Sciences Laboratory for a network integrating human, animal, and environmental data to predict, detect, and mitigate emerging infectious-disease threats in Asia-Pacific.
• Diagnostics: It has funded multiple low-cost molecular and point-of-care diagnostic projects, including a $846,097 grant to DCN Diagnostics and $2.72 million to Rapidemic for molecular diagnosis of infectious diseases.
• Sequencing for surveillance: It also funded the University of Birmingham to develop sequencing directly from cholera stool/wastewater samples to study transmission.
• Animal/infectious-disease surveillance: The Foundation gave the International Livestock Research Institute $1.45 million in 2026 to use advanced analytical tools for early detection and monitoring of infectious diseases.

The Foundation itself explicitly describes genomic sequencing, wastewater/environmental surveillance, and data modeling as tools for improving outbreak detection and public-health decision-making. 

The same capabilities can have different applications:

Capability	Public-health purpose	Why it can be dual-use
Pathogen sequencing	Track outbreaks and variants	Generates detailed pathogen genetic information
Genomic analysis	Determine transmission/evolution	Some information can have security implications
Animal-reservoir surveillance	Identify spillover risks	Maps pathogens and their natural hosts
Diagnostics	Detect infections quickly	Improves ability to recognize particular biological agents
Environmental surveillance	Detect pathogens before clinical outbreaks	Provides information about pathogen presence/distribution

The Gates Foundation funding  of dual use ebola  and coivid research

Examples from its current public grant database:

• Pathogen genomic sequencing: In March 2026, the Foundation committed $25,000 for an economic study concerning procurement and delivery of pathogen genomic sequencing across African public-health programs.
• Genomic analysis: In June 2026, it committed $749,667 to the Broad Institute to develop pathogen-genomic data-analysis pipelines for malaria and other pathogens of public-health importance in Africa.
• One Health / animal-human-environment surveillance: In 2026, it committed $508,992 to Temasek Life Sciences Laboratory for a network integrating human, animal, and environmental data to predict, detect, and mitigate emerging infectious-disease threats in Asia-Pacific.
• Diagnostics: It has funded multiple low-cost molecular and point-of-care diagnostic projects, including a $846,097 grant to DCN Diagnostics and $2.72 million to Rapidemic for molecular diagnosis of infectious diseases.
• Sequencing for surveillance: It also funded the University of Birmingham to develop sequencing directly from cholera stool/wastewater samples to study transmission.
• Animal/infectious-disease surveillance: The Foundation gave the International Livestock Research Institute $1.45 million in 2026 to use advanced analytical tools for early detection and monitoring of infectious diseases.

The Foundation itself explicitly describes genomic sequencing, wastewater/environmental surveillance, and data modeling as tools for improving outbreak detection and public-health decision-making.

Where the "dual-use" issue comes in

The same capabilities can have different applications:

Capability	Public-health purpose	Why it can be dual-use
Pathogen sequencing	Track outbreaks and variants	Generates detailed pathogen genetic information
Genomic analysis	Determine transmission/evolution	Some information can have security implications
Animal-reservoir surveillance	Identify spillover risks	Maps pathogens and their natural hosts
Diagnostics	Detect infections quickly	Improves ability to recognize particular biological agents
Environmental surveillance	Detect pathogens before clinical outbreaks	Provides information about pathogen presence/distribution

The Gates Foundation says its committed-grants database covers grants since 1994 and is dynamically updated; it also makes its funded research publicly accessible.

1. Pathogen genomic sequencing and analysis

One clear category is funding for pathogen genomic sequencing and genomic-data analysis.

The Foundation has funded work involving sequencing and analysis of pathogen genomes for public-health surveillance. It also funds infrastructure intended to make genomic information useful to public-health programs.

Why this is dual-use:
Genomic sequencing is fundamentally a surveillance technology. It can establish which pathogen or lineage is present, reveal relationships between cases, and identify evolutionary changes. Those capabilities are beneficial for outbreak response but also create information that has potential security sensitivity.

The dual-use concern therefore comes primarily from the information and analytical capability, rather than from sequencing itself. There is nothing inherently military about sequencing a pathogen.

2. One Health / human-animal-environment surveillance

A particularly relevant category is the Foundation's support for One Health surveillance, where information from humans, animals, and the environment is combined.

For example, the Foundation's grants database includes funding for the World Organisation for Animal Health (WOAH). A September 2025 grant was $1.88 million for work serving Africa and Asia, while earlier grants supported WOAH's animal-health activities globally and in Africa.

Why this is dual-use:
Animal surveillance can identify:

• pathogens circulating in animal populations;
• geographic areas where spillover may occur;
• relationships between animal and human infections;
• changes in disease prevalence over time.

That information is extremely valuable for preventing zoonotic outbreaks. From a biosecurity perspective, however, systematic knowledge of which pathogens occur where, in which hosts, and under what ecological conditions can also be regarded as sensitive biological intelligence.

3. Emerging-disease surveillance

The broader Gates portfolio supports technologies intended to detect emerging infectious diseases earlier—including genomic surveillance, diagnostics, epidemiological modeling, and environmental surveillance.

The Foundation describes its grantmaking as focused on global health and explicitly maintains a public database of funded projects.

Why this is dual-use:
An effective emerging-disease surveillance system effectively creates a map of:

pathogen → host → location → transmission → genetic characteristics → detection method

That's exactly the kind of information that public-health authorities need to recognize an emerging outbreak quickly. But because the same information describes biological threats in considerable detail, it has an obvious biosecurity intelligence dimension.

4. Environmental surveillance

The Foundation has also supported approaches that detect pathogens in environmental samples—for example, sequencing approaches applied to wastewater or other samples.

Why this is dual-use:
Environmental surveillance can detect circulation of a pathogen without testing every individual. From a public-health standpoint, that's extremely useful because it can provide an early warning.

The security-sensitive aspect is that it potentially allows systematic monitoring of where a biological agent is circulating and how its genetic characteristics change.

The important distinction

Finding	What it establishes
Gates funds sequencing	Yes
Gates funds animal/One Health surveillance	Yes
These capabilities have recognized dual-use potential	Yes
Gates is funding research that could have biosecurity implications	Yes

Ebola

1. Ebola genomic sequencing — Broad Institute, 2015

The Foundation gave the Broad Institute $850,055 to obtain and make current Ebola-virus genetic sequences available, explicitly to support development/deployment of diagnostics, therapeutics, and vaccines during the West African epidemic.

Dual-use relevance:
Sequencing provides knowledge about the genetic composition and evolution of a pathogen and can establish relationships among infections. That's extremely valuable for outbreak control. The same capability is therefore dual-use in principle: pathogen genomic information can have both defensive/public-health and security significance.

2. Ebola diagnostics and response

In 2014 the Foundation committed $50 million to Ebola response, including work on diagnostics, vaccines, therapies, emergency operations, and health-system capacity.

And in 2026, during the Bundibugyo Ebola outbreak in DRC/Uganda, it announced another $15 million, including funding for cross-border surveillance and diagnostics.

Dual-use relevance:
Diagnostic capability gives an organization the ability to detect a particular pathogen rapidly. Surveillance similarly provides information about where transmission is occurring. Those capabilities are obviously useful for defense against biological threats, but they don't constitute biological-weapons development.

---

COVID-19

COVID provides an even stronger example because the Foundation explicitly helped build genomic-surveillance capacity.

3. COVID genomic surveillance

The Foundation says that during COVID it helped build genomic sequencing capacity in lower-income countries and supported countries in detecting variants. It now describes genomic sequencing as a tool for identifying strains, tracking transmission, detecting variants, and informing public-health responses.

It also funded a specific $1.50 million Wits Health Consortium project to conduct genomic surveillance and variant detection of COVID-19 from human and animal sources in South Africa.

This combines:

human surveillance + animal sources + sequencing + variant detection.

Dual-use relevance:
That combination creates substantial epidemiological knowledge about a pathogen's distribution, genetic variation, and relationship between animal and human infections.

4. COVID diagnostics

The Foundation funded the expansion of COVID diagnostic capacity across Africa, including PCR testing and rapid antigen testing.

One example is an $8.78 million Wits Health Consortium grant to implement and validate a high-throughput PCR platform for COVID testing and surveillance, as well as other pathogens.

Another was $4.9 million to Global Access Health for high-volume manufacturing processes and future COVID diagnostic platforms intended to prepare for future pandemics.

Dual-use relevance:
The technology becomes broader than COVID itself when the platform is designed for multiple pathogens. A diagnostic platform capable of detecting numerous infectious agents is inherently relevant to biological-threat detection.

Again, that is primarily a defensive capability but when the tests are faulty it can spread a disases

Capability	Ebola	COVID-19	Dual-use concern
Genomic sequencing	Yes	Yes	Pathogen genetic information
Genomic surveillance	Yes	Yes	Tracking evolution/transmission
Animal-source surveillance	Less prominent in these grants	Yes	Human–animal pathogen interface
Diagnostics	Yes	Extensive	Detection capability
Epidemiological surveillance	Yes	Extensive	Mapping transmission
Vaccine/therapeutic R&D	Yes	Yes	Countermeasure development